2012
DOI: 10.1016/j.vetpar.2011.11.034
|View full text |Cite
|
Sign up to set email alerts
|

Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A

Abstract: We evaluated the humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A. The experiment used 13 mixed-breed pigs divided into the following three groups: G1 (vaccinated-challenged, n=6), which received the rhoptry vaccine (200(g/dose); G2 (adjuvant-challenged, n=4), which received PBS plus Quil-A; and G3 (unvaccinated-challenged, n=3), which was the control group. The treatments were performed intranasally at days 0, 21, and 42. Three p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
16
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 23 publications
(19 citation statements)
references
References 27 publications
2
16
1
Order By: Relevance
“…This adjuvant was described as being capable of inducing strong Th1 and Th2 responses and moderate CTL responses (COX & COULTER, 1997; PAEPENMÜLLER & MÜLLER-GOYMANN, 2014). Additionally, the Quil-A adjuvant is widely used in animals, has a low cost and a simple design, and is generally safe (COX & COULTER, 1997;GARCIA et al, 2007;IGARASHI et al, 2010;CUNHA et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…This adjuvant was described as being capable of inducing strong Th1 and Th2 responses and moderate CTL responses (COX & COULTER, 1997; PAEPENMÜLLER & MÜLLER-GOYMANN, 2014). Additionally, the Quil-A adjuvant is widely used in animals, has a low cost and a simple design, and is generally safe (COX & COULTER, 1997;GARCIA et al, 2007;IGARASHI et al, 2010;CUNHA et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…It has previously been reported that as little as one tissue cyst (containing possibly thousands of infective bradyzoites) is enough to cause infection [ 39 ]. Other research, which has studied the vaccination of pigs to reduce tissue cyst burden, has mainly focused on microscopic identification of tissue cysts and/or detection of parasite DNA from mice used in the bioassay [ 21 , 23 - 25 , 35 , 40 , 41 ]. In these studies there is no detailed information about mouse survival and clinical signs of T. gondii during the bioassay itself.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to mouse survival rates, T. gondii DNA was not detected in any mice (0/45) following challenge with inocula comprised of porcine tissues from G2 pigs (vaccinated and oocysts challenged pigs) (Table 3 ), whilst parasite DNA was detected in 53.3% (24/45) of mice following challenge with inocula from G1 pigs (non-vaccinated oocyst challenged) (Table 4 ). Other research, investigating vaccination and T. gondii challenge of pigs and subsequent mouse bioassay, have focused only on the microscopic detection of tissues cysts from mouse brain following bioassay [ 18 , 21 , 25 , 41 ], rather than detection of T. gondii DNA from the mouse brain. Therefore, as the pathology results from the current research provide limited information, it is difficult to draw direct comparisons between these vaccination and challenge experiments and the current research.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Previous studies have used live vaccines and killed vaccines to protect pigs against T. gondii cyst formation (Dubey et al, 1991(Dubey et al, , 1994Pinckney et al, 1994;Freire et al, 2003;Kringel et al, 2004;Garcia et al, 2005;Cunha et al, 2012;Burrells et al, 2015). However, live vaccines (RH and S48) carry the risk of reverting to virulence and becoming infective for humans; therefore, it is essential to produce a killed vaccine against T. gondii (Burrells et al, 2015).…”
Section: Introductionmentioning
confidence: 99%